12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tasquinimod: Additional Phase II data

Additional data from a double-blind, international Phase II trial in 206 asymptomatic, metastatic CRPC patients showed that low levels of transforming growth factor (TGF) beta 1 (TGFB1) (p=0.029), thrombospondin-1 ( TSP-1; THBS1) (p=0.017) and VEGF-C (p=0.034) at week 8 were correlated with longer survival in patients receiving tasquinimod vs. placebo. Data were presented...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >